



Precision Medicine – efficacy and safety –

The “Challenge”

To date, no single technology or product exists that can simultaneously identify all the genomic additive effects and correlate these with the phenotype of patients affected with cancer or other diseases by identifying genetic variations related to the disease and the patient profile data.

The “Solution”


Using the RKE platform with its multi-dimensional digital twin ecosystem produces actionable, unbiased information. Leveraging the *in silico* testing environment, researchers are identifying relationships by blending disease characteristics with cohort group genomics and matching them to identified patterns in target patient profiles (TPP) to determine specific treatments (molecules and protocols) and matching them to patients.

Contact or Visit

[631-388-0160](tel:631-388-0160)
www.ryailiti.com



Drug Development



UNBIASED SOLUTIONS BASED ON
REAL-WORLD EVIDENCE